Three EU firms describe progress on trial data sharing
This article was originally published in SRA
In August this year, the European R&D drug industry federation EFPIA, in concert with its US counterpart PhRMA, published a set of principles for 'responsible clinical trial data sharing'1. These were a response both generally to the growing international clamour for more trial data transparency and more specifically to the European Medicines Agency's draft policy on data disclosure, which had been issued for consultation a couple of months before2,3.
You may also be interested in...
Coronavirus Notebook: Italy Makes First Use Of EU’s Vaccine Export Control System, More Regulators Issue Guidance On Variants
Ukraine has established a system for issuing emergency use authorizations for COVID-19 vaccines that recognizes authorizations granted by other world regulators.
The Russian backers of the vaccine’s development say that if it receives a marketing authorization in the EU, distribution could begin in June this year.
Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval
Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.